← Leaderboards
Brendan Patrick Lucey
Washington University
$5,788,912
Attributed
$5,788,912
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2014–24$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$5,788,912 · 5
By mechanism
R01$3,099,927 · 1
P01$1,048,460 · 1
K76$982,082 · 1
R21$433,125 · 1
R03$225,318 · 1
Top collaborators
No co-investigators on record.
Most similar at Washington University
Same institution · by research overlap
- John R Cirrito$14,600,160
- John Morris$91,785,862
- David M Holtzman$51,909,630
- Shin-Ichiro Imai$11,081,385
- Barbara Joy Snider$4,853,357
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAffectPathogenesisCerebrospinal FluidS DiseaseSleepImpaired CognitionAmyloidDementiaTau AggregationWakefulnessHypocretinCognitivePolysomnographyAbeta DepositionAmyloid Beta-ProteinIntercellular FluidBrainPharmaceutical PreparationsProductionSamplingMediatingMonitorParticipant
Grant awards (17)
Effect of Suvorexant on Alzheimer's Disease Biomarkers$1,504,459
R01 · FY2024 · AG · contact PI
Effect of Suvorexant on Alzheimer's Disease Biomarkers$1,595,468
R01 · FY2023 · AG · contact PI
Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's Disease$216,019
P01 · FY2023 · AG · contact PI
Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's Disease$214,444
P01 · FY2022 · AG · contact PI
Characterization of Orexin/Hypocretin Kinetics in Alzheimer's Disease$196,875
R21 · FY2022 · AG · contact PI
Characterization of Orexin/Hypocretin Kinetics in Alzheimer's Disease$236,250
R21 · FY2021 · AG · contact PI
Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's Disease$212,554
P01 · FY2021 · AG · contact PI
Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's Disease$203,288
P01 · FY2020 · AG · contact PI
Sleep Quality and Human Amlyoid-Beta Kinetics$155,742
K76 · FY2020 · AG · contact PI
Sleep and Orexin: Potential Markers of Progression from Preclinical to Mildly Symptomatic Alzheimer's Disease$202,155
P01 · FY2019 · AG · contact PI
Sleep Quality and Human Amlyoid-Beta Kinetics$160,141
K76 · FY2019 · AG · contact PI
SLEEP QUALITY AND HUMAN AMLYOID-BETA KINETICS$160,141
K76 · FY2019 · AG · contact PI
Sleep Quality and Human Amlyoid-Beta Kinetics$164,509
K76 · FY2018 · AG · contact PI
Sleep Quality and Human Amlyoid-Beta Kinetics$168,749
K76 · FY2017 · AG · contact PI
Sleep Quality and Human Amlyoid-Beta Kinetics$172,800
K76 · FY2016 · AG · contact PI
SLEEP: A POTENTIAL NOVEL MODULATOR OF ALZHEIMER'S DISEASE PATHOLOGY$110,943
R03 · FY2015 · AG · contact PI
SLEEP: A POTENTIAL NOVEL MODULATOR OF ALZHEIMER'S DISEASE PATHOLOGY$114,375
R03 · FY2014 · AG · contact PI